With respect we send you the manuscript entitled: ‘Adjuvant treatment, tumour recurrences and survival rates of uterine serous carcinomas: a single institution review of 62 women’. We hope that the manuscript is applicable for publication in the Southern African Journal of Gynaecological Oncology.

Uterine serous carcinoma (USC) is one of the high-risk uterine cancers and patients with USC have a poor overall prognosis. These tumours are not well understood due to low incidence and limited published data. There is need for effective adjuvant therapy, however, evidence is lacking and protocols practically do not exist. So the role of different adjuvant treatment regimens remains uncertain. Our study shows that USC patients are at high risk of recurrence, and that even early stage patients may benefit from adjuvant treatment regarding relapse-free and overall survival. Adjuvant chemotherapy, traditionally only given to high stage USC patients, seems to be equally or even more effective in low stage patients than radiotherapy. Therefore, we believe that the results of our study would fit into a renowned international journal covering the field of gynaecological oncology.

This study has been approved by the Mercy Health Human Research Ethics Committee. The manuscript has been approved by all authors and has never been published, or under the consideration for publication elsewhere. This study has no sources of support to acknowledge. The authors have no conflict of interest to declare.

We hope that you will consider this manuscript for publication in your journal and we look forward to hearing from you. Should you have any questions, please do not hesitate to contact us.

Yours faithfully,

Fraukje Pol, MD
On behalf of all co-authors